Glück Conviction Score™ ⓘ
INCY
INCYTE CORP
ⓘ
Eingeschränkte Aussagekraft — erst 61 % der Signal-Gewichte sind mit Daten unterlegt.
🟢
Conviction × Timing — fundamental hohe Conviction trifft auf ein positiv drehendes Timing (Momentum/FTD). Der günstige Quadrant des Modells.
Effektiv: Stark
Hoch
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
57,6
103 neu, 317 erhöht, -1580489K $ netto
Aktivist
20,4
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 97.80 | +11.0 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 96.50 | +12.5 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 100.71 | EMA50: 98.64 | |
| MACD-Histogramm | Bullisch | 10 % | 1.215 | Bullisch | |
| RSI(14) | Bärisch | 10 % | 70.3 | Überkauft | |
| Stoch %K(14) | Bärisch | 5 % | 90.0 | Überkauft | |
| ADX(14)+DI | Neutral | 10 % | 19.4 | +DI: 31.3 / −DI: 13.1 | |
| Z-Score(60) | Bärisch | 5 % | 3.18 | Extrem überkauft | |
| 52W-Position | Bullisch | 5 % | 95.3 % | Hoch 110.57 / Tief 67.26 | |
| Bollinger(20,2σ) | Bärisch | 5 % | 105.1 % | Upper 107.65 / Mid 99.07 / Lower 90.50 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.1564 | R²=0.54 / annualisiert +40.7 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-06-04 | Tray Thomas | Officer, Principal Accounting Officer | Open Market Sale | -2.639 | 100,00 | -263.900,00 | -26,1% | |
| 2026-05-26 | Tray Thomas | Officer, Principal Accounting Officer | Open Market Sale | -2.051 | 97,35 | -199.664,85 | -19,7% | |
| 2026-05-19 | Clancy Paul J | Director | Open Market Sale | -15.000 | 94,93 | -1.423.950,00 | -140,6% | |
| 2026-04-17 | CAGNONI PABLO J | Officer, President, Global Head of R&D | Open Market Sale | -18.667 | 96,50 | -1.801.365,50 | -177,9% | |
| 2026-03-17 | CAGNONI PABLO J | Officer, President, R&D | Open Market Sale | -18.667 | 94,24 | -1.759.178,08 | -173,7% | |
| 2026-02-19 | CAGNONI PABLO J | Officer, President, R&D | Open Market Sale | -18.668 | 100,91 | -1.883.787,88 | -186,0% | |
| 2026-01-07 | Issa Mohamed Khairie | Officer, EVP, Head of US Oncology | Open Market Sale | -10.856 | 109,07 | -1.184.063,92 | -116,9% | |
| 2026-01-05 | Stein Steven H | Officer, EVP & Chief Medical Officer | Open Market Sale | -15.634 | 101,70 | -1.589.977,80 | -157,0% | |
| 2025-12-19 | Tray Thomas | Officer, Principal Accounting Officer | Open Market Sale | -2.774 | 100,00 | -277.400,00 | -27,4% | |
| 2025-12-18 | Tray Thomas | Officer, Principal Accounting Officer | Open Market Sale | -600 | 98,25 | -58.950,00 | -5,8% | |
| 2025-12-17 | Morrissey Michael James | Officer, EVP, Head of Tech. Operations | Open Market Sale | -4.323 | 97,26 | -420.454,98 | -41,5% | |
| 2025-12-16 | Morrissey Michael James | Officer, EVP, Head of Tech. Operations | Open Market Sale | -53.175 | 97,29 | -5.173.395,75 | -510,9% | |
| 2025-12-16 | Morrissey Michael James | Officer, EVP, Head of Tech. Operations | Open Market Sale | -833 | 97,42 | -81.150,86 | -8,0% | |
| 2025-12-11 | Mayes Patrick A | Officer, EVP & Chief Scientific Officer | Open Market Sale | -255 | 94,94 | -24.209,70 | -2,4% | |
| 2025-12-10 | Mayes Patrick A | Officer, EVP & Chief Scientific Officer | Open Market Sale | -5.553 | 95,58 | -530.755,74 | -52,4% | |
| 2025-12-02 | Stein Steven H | Officer, EVP & Chief Medical Officer | Open Market Sale | -20.105 | 102,51 | -2.060.963,55 | -203,5% | |
| 2025-12-01 | Stein Steven H | Officer, EVP & Chief Medical Officer | Open Market Sale | -2.559 | 102,96 | -263.474,64 | -26,0% | |
| 2025-11-24 | Tray Thomas | Officer, Principal Accounting Officer | Open Market Sale | -600 | 103,00 | -61.800,00 | -6,1% | |
| 2025-11-21 | Tray Thomas | Officer, Principal Accounting Officer | Open Market Sale | -169 | 102,00 | -17.238,00 | -1,7% | |
| 2025-11-17 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -278 | 104,36 | -29.012,08 | -2,9% | |
| 2025-11-10 | Hoppenot Herve | Director | Open Market Sale | -187.500 | 105,46 | -19.773.750,00 | -1952,9% | |
| 2025-11-05 | Stein Steven H | Officer, EVP & Chief Medical Officer | Open Market Sale | -5.233 | 102,20 | -534.812,60 | -52,8% | |
| 2025-11-04 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -598 | 101,36 | -60.613,28 | -6,0% | |
| 2025-11-03 | Heeson Lee | Officer, EVP, Head of Incyte Intl | Open Market Sale | -3.074 | 94,02 | -289.017,48 | -28,5% | |
| 2025-10-15 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -277 | 85,13 | -23.581,01 | -2,3% | |
| 2025-10-03 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -3.501 | 85,54 | -299.475,54 | -29,6% | |
| 2025-10-02 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -599 | 87,65 | -52.502,35 | -5,2% | |
| 2025-09-16 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -278 | 83,15 | -23.115,70 | -2,3% | |
| 2025-09-02 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -598 | 84,97 | -50.812,06 | -5,0% | |
| 2025-08-15 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -277 | 86,81 | -24.046,37 | -2,4% | |
| 2025-08-04 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -598 | 75,77 | -45.310,46 | -4,5% | |
| 2025-07-21 | Stein Steven H | Officer, EVP & Chief Medical Officer | Open Market Sale | -3.706 | 67,94 | -251.785,64 | -24,9% | |
| 2025-07-16 | Iyengar Vijay K | Officer, EVP, GMAPPS | Open Market Sale | -983 | 68,36 | -67.197,88 | -6,6% | |
| 2025-07-16 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -785 | 68,36 | -53.662,60 | -5,3% | |
| 2025-07-16 | Flannelly Barry P | Officer, EVP & General Manager US | Open Market Sale | -1.340 | 68,36 | -91.602,40 | -9,0% | |
| 2025-07-15 | Iyengar Vijay K | Officer, EVP, GMAPPS | Open Market Sale | -1.177 | 69,86 | -82.225,22 | -8,1% | |
| 2025-07-15 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -3.330 | 69,86 | -232.633,80 | -23,0% | |
| 2025-07-15 | Flannelly Barry P | Officer, EVP & General Manager US | Open Market Sale | -1.192 | 69,86 | -83.273,12 | -8,2% | |
| 2025-07-14 | Stein Steven H | Officer, EVP & Chief Medical Officer | Open Market Sale | -14.952 | 68,47 | -1.023.763,44 | -101,1% | |
| 2025-07-03 | Iyengar Vijay K | Officer, EVP, GMAPPS | Open Market Sale | -5.935 | 68,15 | -404.470,25 | -39,9% | |
| 2025-07-03 | Flannelly Barry P | Officer, EVP & General Manager US | Open Market Sale | -10.903 | 68,15 | -743.039,45 | -73,4% | |
| 2025-07-03 | Iyengar Vijay K | Officer, EVP, GMAPPS | Open Market Sale | -2.682 | 68,16 | -182.805,12 | -18,1% | |
| 2025-07-02 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -599 | 68,61 | -41.097,39 | -4,1% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 30.744.412 | 30.743.991 | 421 | 2.893.664.057 | Aufgestockt | 0,0% | |
| VANGUARD GROUP INC | 19.911.434 | 0 | 19.911.434 | 1.966.652.336 | Neu | +100,0% | |
| BlackRock, Inc. | 18.978.198 | 18.327.923 | 650.275 | 1.786.227.957 | Aufgestockt | +3,5% | |
| DODGE & COX | 12.252.356 | 13.261.742 | -1.009.386 | 1.153.191.747 | Reduziert | -7,6% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 10.930.066 | 0 | 10.930.066 | 1.028.737.812 | Neu | +100,0% | |
| STATE STREET CORP | 9.641.384 | 9.656.403 | -15.019 | 907.447.062 | Reduziert | -0,2% | |
| AQR CAPITAL MANAGEMENT LLC | 5.807.930 | 6.720.024 | -912.094 | 536.130.025 | Reduziert | -13,6% | |
| GEODE CAPITAL MANAGEMENT, LLC | 4.703.184 | 4.993.012 | -289.828 | 441.081.113 | Reduziert | -5,8% | |
| Invesco Ltd. | 3.870.764 | 3.473.781 | 396.983 | 364.316.308 | Aufgestockt | +11,4% | |
| RENAISSANCE TECHNOLOGIES LLC | 3.651.532 | 3.978.332 | -326.800 | 343.682.192 | Reduziert | -8,2% | |
| WELLINGTON MANAGEMENT GROUP LLP | 3.266.136 | 739.378 | 2.526.758 | 307.408.721 | Aufgestockt | +341,7% | |
| MORGAN STANLEY | 2.850.328 | 2.663.823 | 186.505 | 268.272.995 | Aufgestockt | +7,0% | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2.830.799 | 3.094.460 | -263.661 | 266.434.802 | Reduziert | -8,5% | |
| Robeco Institutional Asset Management B.V. | 2.514.383 | 2.480.793 | 33.590 | 236.653.725 | Aufgestockt | +1,4% | |
| GOLDMAN SACHS GROUP INC | 2.351.221 | 1.283.694 | 1.067.527 | 221.296.953 | Aufgestockt | +83,2% | |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 2.144.847 | 2.288.874 | -144.027 | 201.873.001 | Reduziert | -6,3% | |
| DIMENSIONAL FUND ADVISORS LP | 1.975.544 | 1.788.190 | 187.354 | 185.872.809 | Aufgestockt | +10,5% | |
| NORTHERN TRUST CORP | 1.849.726 | 1.760.843 | 88.883 | 174.096.211 | Aufgestockt | +5,0% | |
| Pacer Advisors, Inc. | 1.703.271 | 0 | 1.703.271 | 168.232.077 | Neu | +100,0% | |
| VICTORY CAPITAL MANAGEMENT INC | 1.742.870 | 1.453.664 | 289.206 | 164.038.924 | Aufgestockt | +19,9% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.729.102 | 1.732.639 | -3.537 | 162.743.080 | Reduziert | -0,2% | |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1.717.978 | 2.284.317 | -566.339 | 161.696.089 | Reduziert | -24,8% | |
| Legal & General Group Plc | 1.543.188 | 1.469.147 | 74.041 | 145.244.858 | Aufgestockt | +5,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.540.913 | 1.574.718 | -33.805 | 145.030.732 | Reduziert | -2,1% | |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 1.520.486 | 1.111.193 | 409.293 | 143.108.142 | Aufgestockt | +36,8% | |
| FIRST TRUST ADVISORS LP | 1.500.792 | 1.276.586 | 224.206 | 141.254.538 | Aufgestockt | +17,6% | |
| NORGES BANK | 1.244.233 | 0 | 1.244.233 | 122.892.893 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 1.264.195 | 1.273.170 | -8.975 | 118.986.033 | Reduziert | -0,7% | |
| MARSHALL WACE, LLP | 1.253.138 | 1.072.491 | 180.647 | 117.945.349 | Aufgestockt | +16,8% | |
| PANAGORA ASSET MANAGEMENT INC | 1.210.909 | 992.115 | 218.794 | 113.970.755 | Aufgestockt | +22,1% | |
| FMR LLC | 1.172.890 | 1.246.439 | -73.549 | 110.392.397 | Reduziert | -5,9% | |
| UBS Group AG | 1.140.236 | 682.315 | 457.921 | 107.319.012 | Aufgestockt | +67,1% | |
| AustralianSuper Pty Ltd | 1.137.143 | 640.733 | 496.410 | 107.027.899 | Aufgestockt | +77,5% | |
| ROYAL BANK OF CANADA | 1.054.123 | 1.116.382 | -62.259 | 99.212.000 | Reduziert | -5,6% | |
| Amundi | 1.003.969 | 774.186 | 229.783 | 94.493.562 | Aufgestockt | +29,7% | |
| BNP Paribas Asset Management Holding S.A. | 938.848 | 978.112 | -39.264 | 88.454.880 | Reduziert | -4,0% | |
| Man Group plc | 930.171 | 1.099.329 | -169.158 | 87.547.695 | Reduziert | -15,4% | |
| BANK OF AMERICA CORP /DE/ | 915.527 | 1.003.440 | -87.913 | 86.169.433 | Reduziert | -8,8% | |
| Pictet Asset Management Holding SA | 916.188 | 1.315.666 | -399.478 | 84.787.753 | Reduziert | -30,4% | |
| VIRGINIA RETIREMENT SYSTEMS ET Al | 768.325 | 0 | 768.325 | 75.887.460 | Neu | +100,0% | |
| Skandinaviska Enskilda Banken AB (publ) | 754.116 | 0 | 754.116 | 74.499.120 | Neu | +100,0% | |
| SOUND SHORE MANAGEMENT INC /CT/ | 767.829 | 929.832 | -162.003 | 72.268.065 | Reduziert | -17,4% | |
| SEI INVESTMENTS CO | 714.558 | 663.446 | 51.112 | 67.254.073 | Aufgestockt | +7,7% | |
| FRANKLIN RESOURCES INC | 693.785 | 550.096 | 143.689 | 65.299.043 | Aufgestockt | +26,1% | |
| RHUMBLINE ADVISERS | 693.665 | 684.283 | 9.382 | 65.287.647 | Aufgestockt | +1,4% | |
| Gotham Asset Management, LLC | 676.670 | 352.695 | 323.975 | 63.688.180 | Aufgestockt | +91,9% | |
| ARMISTICE CAPITAL, LLC | 656.817 | 1.098.102 | -441.285 | 61.819.616 | Reduziert | -40,2% | |
| SEB Asset Management AB | 646.168 | 0 | 646.168 | 60.817.276 | Neu | +100,0% | |
| Russell Investments Group, Ltd. | 638.242 | 743.307 | -105.065 | 59.704.374 | Reduziert | -14,1% | |
| CANADA PENSION PLAN INVESTMENT BOARD | 607.944 | 638.694 | -30.750 | 57.219.689 | Reduziert | -4,8% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 30.744.412 | 30.743.991 | 0,0% | 2.893.664.057 | 16,78 |
| BlackRock, Inc. | 18.978.198 | 18.327.923 | +3,5% | 1.786.227.957 | 10,36 |
| DODGE & COX | 12.252.356 | 13.261.742 | -7,6% | 1.153.191.747 | 6,69 |
| VANGUARD CAPITAL MANAGEMENT LLC | 10.930.066 | 0 | +100,0% | 1.028.737.812 | 5,97 |
| STATE STREET CORP | 9.641.384 | 9.656.403 | -0,2% | 907.447.062 | 5,26 |
| AQR CAPITAL MANAGEMENT LLC | 5.807.930 | 6.720.024 | -13,6% | 536.130.025 | 3,11 |
| GEODE CAPITAL MANAGEMENT, LLC | 4.703.184 | 4.993.012 | -5,8% | 441.081.113 | 2,56 |
| Invesco Ltd. | 3.870.764 | 3.473.781 | +11,4% | 364.316.308 | 2,11 |
| RENAISSANCE TECHNOLOGIES LLC | 3.651.532 | 3.978.332 | -8,2% | 343.682.192 | 1,99 |
| WELLINGTON MANAGEMENT GROUP LLP | 3.266.136 | 739.378 | +341,7% | 307.408.721 | 1,78 |
| MORGAN STANLEY | 2.850.328 | 2.663.823 | +7,0% | 268.272.995 | 1,56 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2.830.799 | 3.094.460 | -8,5% | 266.434.802 | 1,55 |
| Robeco Institutional Asset Management B.V. | 2.514.383 | 2.480.793 | +1,4% | 236.653.725 | 1,37 |
| GOLDMAN SACHS GROUP INC | 2.351.221 | 1.283.694 | +83,2% | 221.296.953 | 1,28 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 2.144.847 | 2.288.874 | -6,3% | 201.873.001 | 1,17 |
| DIMENSIONAL FUND ADVISORS LP | 1.975.544 | 1.788.190 | +10,5% | 185.872.809 | 1,08 |
| NORTHERN TRUST CORP | 1.849.726 | 1.760.843 | +5,0% | 174.096.211 | 1,01 |
| VICTORY CAPITAL MANAGEMENT INC | 1.742.870 | 1.453.664 | +19,9% | 164.038.924 | 0,95 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.729.102 | 1.732.639 | -0,2% | 162.743.080 | 0,94 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1.717.978 | 2.284.317 | -24,8% | 161.696.089 | 0,94 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 797 | 213,2 | 19.233 |
| 31.12.2025 | ✓ | 805 | 207,2 | 19.458 |
| 30.09.2025 | ✓ | 713 | 205,2 | 16.481 |
| 30.06.2025 | ✓ | 653 | 200,0 | 12.749 |
| 31.03.2025 | ✓ | 626 | 196,6 | 11.196 |
| 31.12.2024 | ✓ | 628 | 190,1 | 12.414 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| NORGES BANK | 1.244.233 | 122.892.893 |
| GLENMEDE TRUST CO NA | 549.006 | 54.225.322 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 323.124 | 31.915.000 |
| Eurizon Capital SGR S.p.A. | 164.371 | 16.235.102 |
| Avoro Capital Advisors LLC | 135.000 | 13.333.950 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 128.384 | 12.680.488 |
| PINEBRIDGE INVESTMENTS LLC | 101.254 | 10.000.858 |
| Atle Fund Management AB | 70.851 | 6.997.953 |
| Beacon Harbor Wealth Advisors, Inc. | 68.069 | 6.723.175 |
| Munich Reinsurance Co Stock Corp in Munich | 61.319 | 6.065.062 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| MARSHALL WACE, LLP | 1.072.491 | 1.056.451 | +6586.4 % | 105.929.937 |
| WELLINGTON MANAGEMENT GROUP LLP | 739.378 | 718.294 | +3406.8 % | 73.028.364 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 2.284.317 | 540.523 | +31.0 % | 225.621.990 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 2.288.874 | 527.703 | +30.0 % | 211.926.843 |
| FIRST TRUST ADVISORS LP | 1.276.586 | 520.260 | +68.8 % | 126.088.442 |
| GEODE CAPITAL MANAGEMENT, LLC | 4.993.012 | 506.842 | +11.3 % | 491.499.628 |
| Pictet Asset Management Holding SA | 1.315.666 | 489.382 | +59.2 % | 130.145.237 |
| WORLDQUANT MILLENNIUM ADVISORS LLC | 531.693 | 459.051 | +631.9 % | 52.515.318 |
| Pacer Advisors, Inc. | 1.703.271 | 454.629 | +36.4 % | 168.232.077 |
| BNP Paribas Asset Management Holding S.A. | 978.112 | 446.605 | +84.0 % | 96.612 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| Bellevue Group AG | 4.773 | -1.435.913 | -99.7 % | 471.429 |
| AQR CAPITAL MANAGEMENT LLC | 6.720.024 | -1.203.487 | -15.2 % | 663.736.788 |
| Man Group plc | 1.099.329 | -834.218 | -43.1 % | 108.580.725 |
| UBS Group AG | 682.315 | -773.367 | -53.1 % | 67.392.253 |
| DODGE & COX | 13.261.742 | -670.674 | -4.8 % | 1.309.862.257 |
| RENAISSANCE TECHNOLOGIES LLC | 3.978.332 | -549.800 | -12.1 % | 392.939.852 |
| PANAGORA ASSET MANAGEMENT INC | 992.115 | -486.257 | -32.9 % | 97.991.199 |
| ACADIAN ASSET MANAGEMENT LLC | 1.844.752 | -396.456 | -17.7 % | 182.169 |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 1.111.193 | -386.820 | -25.8 % | 109.752.533 |
| BANK OF AMERICA CORP /DE/ | 1.003.440 | -370.395 | -27.0 % | 99.109.792 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 14.05.2026 | Dodge & Cox | Passiv (13G/A) | 6,20 % | 12.252.356 | Neu | |
| 11.05.2026 | FBB3 LLC | Aktivist (13D/A) | 0,02 % | 31.140 | 0,00 pp | Item 4 of Schedule 13D is supplemented and superseded, as the case may be, as follows: … |
| 11.05.2026 | FBB Associates | Aktivist (13D/A) | 0,02 % | 33.410 | 0,00 pp | Item 4 of Schedule 13D is supplemented and superseded, as the case may be, as follows: … |
| 11.05.2026 | Baker Bros. Advisors LP | Aktivist (13D/A) | 15,40 % | 30.865.077 | -0,10 pp | Item 4 of Schedule 13D is supplemented and superseded, as the case may be, as follows: … |
| 11.05.2026 | FBB2, LLC | Aktivist (13D/A) | 0,01 % | 14.755 | 0,00 pp | Item 4 of Schedule 13D is supplemented and superseded, as the case may be, as follows: … |
| 11.05.2026 | Felix J. Baker | Aktivist (13D/A) | 15,60 % | 31.225.572 | -0,10 pp | Item 4 of Schedule 13D is supplemented and superseded, as the case may be, as follows: … |
| 11.05.2026 | Baker Bros. Advisors (GP) LLC | Aktivist (13D/A) | 15,40 % | 30.865.077 | -0,10 pp | Item 4 of Schedule 13D is supplemented and superseded, as the case may be, as follows: … |
| 11.05.2026 | Julian C. Baker | Aktivist (13D/A) | 15,60 % | 31.223.155 | -0,10 pp | Item 4 of Schedule 13D is supplemented and superseded, as the case may be, as follows: … |
| 30.04.2026 | Vanguard Capital Management | Passiv (13G) | 6,32 % | 12.591.630 | Neu | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -10,05 pp | |
| 10.02.2026 | FBB Associates | Aktivist (13D/A) | 0,02 % | 33.410 | +0,01 pp | |
| 10.02.2026 | FBB2, LLC | Aktivist (13D/A) | 0,01 % | 14.755 | 0,00 pp | |
| 10.02.2026 | Baker Bros. Advisors (GP) LLC | Aktivist (13D/A) | 15,50 % | 30.852.922 | -0,60 pp | |
| 10.02.2026 | Felix J. Baker | Aktivist (13D/A) | 15,70 % | 31.213.417 | -0,60 pp | |
| 10.02.2026 | Baker Bros. Advisors LP | Aktivist (13D/A) | 15,50 % | 30.852.922 | -0,60 pp | |
| 10.02.2026 | FBB3 LLC | Aktivist (13D/A) | 0,02 % | 31.140 | 0,00 pp | |
| 10.02.2026 | Julian C. Baker | Aktivist (13D/A) | 15,70 % | 31.211.000 | -0,60 pp | |
| 10.11.2025 | STATE STREET CORPORATION | Passiv (13G) | 5,00 % | 9.677.414 | -0,50 pp | |
| 17.10.2025 | BlackRock, Inc. | Passiv (13G/A) | 7,80 % | 15.242.171 | Neu | |
| 08.11.2024 | . BlackRock, Inc. | Passiv (13G) | 8,90 % | 17.077.446 | 0,00 pp | |
| 21.10.2024 | . BlackRock, Inc. | Passiv (13G) | 8,90 % | 17.077.446 | -1,90 pp | |
| 17.10.2024 | STATE STREET CORPORATION | Passiv (13G) | 5,50 % | 10.552.047 | Neu | |
| 14.06.2024 | FBB3 LLC | Aktivist (13D/A) | 0,02 % | 31.140 | +0,01 pp | |
| 14.06.2024 | Felix J. Baker | Aktivist (13D/A) | 16,30 % | 31.209.896 | 0,00 pp | |
| 14.06.2024 | Baker Bros. Advisors (GP) LLC | Aktivist (13D/A) | 16,10 % | 30.849.401 | 0,00 pp | |
| 14.06.2024 | FBB2, LLC | Aktivist (13D/A) | 0,01 % | 14.755 | 0,00 pp | |
| 14.06.2024 | FBB Associates | Aktivist (13D/A) | 0,01 % | 33.410 | 0,00 pp | |
| 14.06.2024 | Baker Bros. Advisors LP | Aktivist (13D/A) | 16,10 % | 30.849.401 | 0,00 pp | |
| 14.06.2024 | Julian C. Baker | Aktivist (13D/A) | 16,30 % | 31.207.479 | 0,00 pp | |
| 13.05.2024 | FBB Associates | Aktivist (13D/A) | 0,01 % | 33.410 | 0,00 pp | |
| 13.05.2024 | Felix J. Baker | Aktivist (13D/A) | 16,30 % | 36.669.079 | 0,00 pp | |
| 13.05.2024 | Baker Bros. Advisors LP | Aktivist (13D/A) | 16,10 % | 36.308.584 | -0,10 pp | |
| 13.05.2024 | Julian C. Baker | Aktivist (13D/A) | 16,30 % | 36.666.662 | 0,00 pp | |
| 13.05.2024 | FBB2, LLC | Aktivist (13D/A) | 0,01 % | 14.755 | 0,00 pp | |
| 13.05.2024 | FBB3 LLC | Aktivist (13D/A) | 0,01 % | 31.140 | 0,00 pp | |
| 13.05.2024 | Baker Bros. Advisors (GP) LLC | Aktivist (13D/A) | 16,10 % | 36.308.584 | -0,10 pp | |
| 09.05.2024 | Julian C. Baker | Aktivist (13D/A) | 16,30 % | 36.666.662 | -0,10 pp | |
| 09.05.2024 | Baker Bros. Advisors (GP) LLC | Aktivist (13D/A) | 16,20 % | 36.308.584 | -0,10 pp | |
| 09.05.2024 | FBB3 LLC | Aktivist (13D/A) | 0,01 % | 31.140 | 0,00 pp | |
| 09.05.2024 | FBB Associates | Aktivist (13D/A) | 0,01 % | 33.410 | -0,01 pp |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 15.05.2025 | Rob Bresnahan | – | House | Verkauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Stammdaten
Incyte Corporation, ein Biopharmaunternehmen, konzentriert sich auf die Entdeckung, Entwicklung und Vermarktung patentierter Therapeutika in den Vereinigten Staaten und international. Das Unternehmen bietet JAKAFI, ein Medikament zur Behandlung von Myelofibrose und Polycythemia vera; PEMAZYRE, einen Fibroblastenwachstumsfaktor-Rezeptor-Kinase-Inhibitor, der in verschiedenen flüssigen und soliden Tumortypen als onkogene Treiber wirkt; und ICLUSIG, einen Kinase-Inhibitor zur Behandlung von chronischer Leukämie und Philadelphia-Chromosom-positiver akuter lymphoblastischer Leukämie. Seine klinischen Produktkandidaten umfassen Ruxolitinib zur Behandlung von steroidrefraktärem chronischem Graft-versus-Host-Disease (GVHD); Itacitinib, das sich in Phase II/III klinischen Studien zur Behandlung von naivem chronischem GVHD befindet; und Pemigatinib zur Behandlung von Blasenkrebs, Cholangiokarziom, Myeloproliferativen Syndrom und Tumor-agnostisch. Darüber hinaus entwickelt das Unternehmen Parsaclisib, das sich in Phase II klinischen Studien für follikuläres Lymphom, Marginalzone-Lymphom und Mantelzell-Lymphom befindet. Zusätzlich entwickelt es Retifanlimab, das sich in Phase II klinischen Studien für MSI-high endometriales Karzinom, Merkel-Zellkarzinom und Analkarzinom sowie in Phase II klinischen Studien für Patienten mit nicht-kleinzelligem Lungenkrebs befindet. Das Unternehmen hat Kooperationsvereinbarungen mit Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; und Nimble Therapeutics sowie klinische Kooperationen mit MorphoSys AG und Xencor, Inc. zur Untersuchung der Kombination von Tafasitamab, Plamotamab und Lenalidomid bei Patienten mit rezidiviertem oder refraktärem diffusem großzelligem B-Zell-Lymphom und rezidiviertem oder refraktärem follikulärem Lymphom. Das Unternehmen wurde 1991 gegründet und hat seinen Hauptsitz in Wilmington, Delaware.
Unternehmen & Branche
| Name | INCYTE CORP |
|---|---|
| Ticker | INCY |
| CIK | 0000879169 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 8731 · Services-Commercial Physical & Biological Research |
Wertpapier & Kennzahlen
| CUSIP | 45337c102 |
|---|---|
| ISIN | US45337C1027 |
| Typ | Common Stock |
| Marktkapitalisierung | 20,92 Mrd. USD |
| KGV (P/E) | 16,44 |
| Beta | 0,79 |
Bewertung
| KBV (P/B) | 4,05 vs. 4,30 (2021) ▼ |
|---|---|
| KUV (P/S) | 4,07 vs. 5,43 (2021) ▼ |
| EV/EBITDA | 11,1 vs. 22,1 (2021) ▼ |
| FCF-Rendite | 6,8 % vs. 4,6 % (2021) ▲ |
| Buyback-Rendite | 0,0 % |
Qualität & Bilanz
| Bruttomarge | 92,8 % vs. 94,9 % (2021) ▼ |
|---|---|
| Operative Marge | 29,5 % vs. 19,6 % (2021) ▲ |
| Nettomarge | 25,0 % vs. 31,8 % (2021) ▼ |
| ROIC | 24,6 % vs. 24,8 % (2021) ≈ |
| Nettoverschuldung/EBITDA | -1,9 vs. -3,1 (2021) ▲ |
| Zinsdeckungsgrad | 623,9 vs. 307,0 (2021) ▲ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 4,30 | 4,09 | 2,71 | 3,88 | 3,79 | |
| KUV (P/S) | 5,43 | 5,27 | 3,81 | 3,15 | 3,81 | |
| EV/EBITDA | 22,1 | 23,2 | 15,5 | 77,9 | 10,3 | |
| FCF-Rendite | 4,6 % | 5,4 % | 3,5 % | 2,5 % | 7,2 % | |
| Buyback-Rendite | – | 0,0 % | 0,0 % | 15,0 % | 0,0 % | |
| Qualität & Bilanz | ||||||
| Bruttomarge | 94,9 % | 93,9 % | 93,1 % | 92,6 % | 92,8 % | |
| Operative Marge | 19,6 % | 17,1 % | 16,8 % | 1,4 % | 29,5 % | |
| Nettomarge | 31,8 % | 10,0 % | 16,2 % | 0,8 % | 25,0 % | |
| ROIC | 24,8 % | 7,7 % | 11,4 % | 0,9 % | 24,6 % | |
| Nettoverschuldung/EBITDA | -3,1 | -4,5 | -4,5 | -10,8 | -1,9 | |
| Zinsdeckungsgrad | 307,0 | 217,3 | 243,2 | 26,9 | 623,9 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 1.272.676.000 | 303.330.000 | 1,47 | 7.339.113.000 | 5.622.847.000 |
| 2025-12-31 | 10-K | 5.141.242.000 | 1.286.650.000 | 6,41 | 6.957.973.000 | 5.167.478.000 |
| 2025-09-30 | 10-Q | 1.365.980.000 | 424.169.000 | 2,11 | 6.330.356.000 | 4.651.194.000 |
| 2025-06-30 | 10-Q | 1.215.529.000 | 404.999.000 | 2,04 | 5.821.354.000 | 4.170.903.000 |
| 2025-03-31 | 10-Q | 1.052.898.000 | 158.203.000 | 0,80 | 5.749.365.000 | 3.667.563.000 |
| 2024-12-31 | 10-K | 4.241.217.000 | 32.615.000 | 0,15 | 5.444.322.000 | 3.447.628.000 |
| 2024-09-30 | 10-Q | 1.137.871.000 | 106.456.000 | 0,54 | 5.012.434.000 | 3.171.220.000 |
| 2024-06-30 | 10-Q | 1.043.759.000 | -444.601.000 | -2,04 | 4.661.803.000 | 2.997.059.000 |
| 2024-03-31 | 10-Q | 880.889.000 | 169.548.000 | 0,75 | 7.135.605.000 | 5.394.271.000 |
| 2023-12-31 | 10-K | 3.695.649.000 | 597.599.000 | 2,65 | 6.782.107.000 | 5.189.837.000 |
| 2023-09-30 | 10-Q | 919.025.000 | 171.269.000 | 0,76 | 6.388.239.000 | 4.931.447.000 |
| 2023-06-30 | 10-Q | 954.610.000 | 203.548.000 | 0,90 | 6.208.259.000 | 4.740.692.000 |
| 2023-03-31 | 10-Q | 808.673.000 | 21.703.000 | 0,10 | 5.797.623.000 | 4.462.568.000 |
| 2022-12-31 | 10-K | 3.394.635.000 | 340.660.000 | 1,52 | 5.840.984.000 | 4.370.119.000 |
| 2022-09-30 | 10-Q | 823.303.000 | 112.775.000 | 0,50 | 5.510.214.000 | 4.226.651.000 |
| 2022-06-30 | 10-Q | 911.397.000 | 161.432.000 | 0,72 | 5.319.035.000 | 4.085.061.000 |
| 2022-03-31 | 10-Q | 733.235.000 | 37.992.000 | 0,17 | 5.054.221.000 | 3.863.072.000 |
| 2021-12-31 | 10-K | 2.986.267.000 | 948.581.000 | 4,27 | 4.933.352.000 | 3.770.004.000 |
| 2021-09-30 | 10-Q | 812.987.000 | 181.739.000 | 0,82 | 4.198.831.000 | 3.148.657.000 |
| 2021-06-30 | 10-Q | 705.709.000 | 149.456.000 | 0,67 | 3.904.623.000 | 2.935.861.000 |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Product | 4,4 Mrd. | 3,6 Mrd. | 3,2 Mrd. | 2,7 Mrd. | 2,3 Mrd. | 43,0 % | +20,3% | |
| JAKAFI | 3,1 Mrd. | 2,8 Mrd. | 2,6 Mrd. | 2,4 Mrd. | – | 30,5 % | +10,8% | |
| OPZELURA | 678,5 Mio. | 508,3 Mio. | 337,9 Mio. | 128,7 Mio. | – | 6,7 % | +33,5% | |
| Royalty | 636,9 Mio. | 579,3 Mio. | 523,5 Mio. | 482,7 Mio. | 569,3 Mio. | 6,3 % | +9,9% | |
| JAKAVIRoyalty Revenues | 457,7 Mio. | 418,8 Mio. | 367,6 Mio. | 331,6 Mio. | – | 4,5 % | +9,3% | |
| NIKTIMVO | 151,6 Mio. | – | – | – | – | 1,5 % | Neu | |
| Milestone And Contract Revenues | 150,0 Mio. | 43,0 Mio. | 7,0 Mio. | 165,0 Mio. | – | 1,5 % | +248,8% | |
| Olumiant Royalty | 144,6 Mio. | 135,6 Mio. | 136,1 Mio. | 134,5 Mio. | – | 1,4 % | +6,7% | |
| MINJUVIMONJUVI | 144,6 Mio. | 119,2 Mio. | 37,1 Mio. | 19,7 Mio. | – | 1,4 % | +21,3% | |
| ICLUSIG | 134,1 Mio. | 114,3 Mio. | 111,6 Mio. | 105,8 Mio. | – | 1,3 % | +17,3% | |
| Pemazyre | 86,7 Mio. | 81,7 Mio. | 83,6 Mio. | 83,4 Mio. | – | 0,9 % | +6,1% | |
| ZYNYZ | 66,4 Mio. | 3,2 Mio. | 1,3 Mio. | – | – | 0,7 % | +1983,2% | |
| TABRECTARoyalty Revenues | 26,7 Mio. | 22,7 Mio. | 17,8 Mio. | 15,4 Mio. | – | 0,3 % | +17,4% | |
| Other Product Royalty Revenues | 7,9 Mio. | – | – | – | – | 0,1 % | Neu | |
| PEMAZYRERoyalty Revenues | – | 2,2 Mio. | 2,0 Mio. | 1,2 Mio. | – | – | – | |
| Milestone And Contract Revenue | – | – | – | – | 95,0 Mio. | – | – |
Regionen
| Region | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| US | 4,8 Mrd. | 4,0 Mrd. | 3,5 Mrd. | 3,2 Mrd. | 2,9 Mrd. | 93,4 % | +20,0% | |
| Europe | 323,7 Mio. | 260,4 Mio. | 175,9 Mio. | 147,0 Mio. | 124,1 Mio. | 6,3 % | +24,3% | |
| Other Countries | 17,6 Mio. | 6,2 Mio. | 4,9 Mio. | – | – | 0,3 % | +183,3% |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 28.04.2026 | 1,3 Mrd. USD | 1,47 |
| Q3 2025 | 30.09.2025 | 28.10.2025 | 1,4 Mrd. USD | 2,11 |
| Q2 2025 | 30.06.2025 | 28.10.2025 | 1,2 Mrd. USD | 2,04 |
| Q1 2025 | 31.03.2025 | 28.04.2026 | 1,1 Mrd. USD | 0,80 |
| Q3 2024 | 30.09.2024 | 28.10.2025 | 1,1 Mrd. USD | 0,54 |
| Q2 2024 | 30.06.2024 | 28.10.2025 | 1,0 Mrd. USD | -2,04 |
| Q1 2024 | 31.03.2024 | 28.10.2025 | 880,9 Mio. USD | 0,75 |
| Q3 2023 | 30.09.2023 | 29.10.2024 | 919,0 Mio. USD | 0,76 |
| Q2 2023 | 30.06.2023 | 29.10.2024 | 954,6 Mio. USD | 0,90 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 28.04.2026 | 10-Q | – | – | SEC » |
| 10.02.2026 | 10-K | 31.12.2025 | 41 Tage | SEC » |
| 28.10.2025 | 10-Q | 30.09.2025 | 28 Tage | SEC » |
| 29.07.2025 | 10-Q | 30.06.2025 | 29 Tage | SEC » |
| 29.04.2025 | 10-Q | 31.03.2025 | 29 Tage | SEC » |
| 10.02.2025 | 10-K | 31.12.2024 | 41 Tage | SEC » |
| 29.10.2024 | 10-Q | 30.09.2024 | 29 Tage | SEC » |
| 30.07.2024 | 10-Q | 30.06.2024 | 30 Tage | SEC » |
| 30.04.2024 | 10-Q | 31.03.2024 | 30 Tage | SEC » |
| 16.02.2024 | 10-K/A | 31.12.2023 | 47 Tage | SEC » |
| 13.02.2024 | 10-K | 31.12.2023 | 44 Tage | SEC » |
| 31.10.2023 | 10-Q | 30.09.2023 | 31 Tage | SEC » |
| 01.08.2023 | 10-Q | 30.06.2023 | 32 Tage | SEC » |
| 02.05.2023 | 10-Q | 31.03.2023 | 32 Tage | SEC » |
| 07.02.2023 | 10-K | 31.12.2022 | 38 Tage | SEC » |
| 01.11.2022 | 10-Q | 30.09.2022 | 32 Tage | SEC » |
| 02.08.2022 | 10-Q | 30.06.2022 | 33 Tage | SEC » |
| 03.05.2022 | 10-Q | 31.03.2022 | 33 Tage | SEC » |
| 08.02.2022 | 10-K | 31.12.2021 | 39 Tage | SEC » |
| 02.11.2021 | 10-Q | 30.09.2021 | 33 Tage | SEC » |
| 03.08.2021 | 10-Q | 30.06.2021 | 34 Tage | SEC » |
| 04.05.2021 | 10-Q | 31.03.2021 | 34 Tage | SEC » |
| 09.02.2021 | 10-K | 31.12.2020 | 40 Tage | SEC » |
| 05.11.2020 | 10-Q | 30.09.2020 | 36 Tage | SEC » |
| 04.08.2020 | 10-Q | 30.06.2020 | 35 Tage | SEC » |
Filing-Analyse (10-K / 10-Q)
Narrative-Analyse der letzten Quartals-/Jahresberichte durch Claude (nur Coverage-Gruppen-Mitglieder). Keine Anlageberatung — der qualitative Score dient der Einordnung, nicht als Kaufempfehlung; siehe allgemeiner Hinweis am Seitenende.
| Datum | Form | Stimmung | Guidance | Qualitativ | Zusammenfassung | |
|---|---|---|---|---|---|---|
| 10.02.2026 | 10-K | 0,45 | ? | 70,0 | Incyte erzielte 2025 ein starkes Umsatzwachstum von 21% auf 5,14 Mrd. USD, getragen von JAKAFI (+10,7%), OPZELURA (+33,5%) sowie den Neulanc… | |
|
Zusammenfassung: Incyte erzielte 2025 ein starkes Umsatzwachstum von 21% auf 5,14 Mrd. USD, getragen von JAKAFI (+10,7%), OPZELURA (+33,5%) sowie den Neulancierungen NIKTIMVO und ZYNYZ. Das Nettoergebnis sprang auf 1,29 Mrd. USD, profitierte jedoch wesentlich vom einmaligen Buchgewinn von 242 Mio. USD aus dem Novartis-Royalty-Vergleich und dem Wegfall der Escient-IPR&D-Abschreibung (679 Mio. USD) aus 2024. Strukturell belastend bleibt der JAKAFI-Patent-Cliff im Jahr 2028, die laufende CMS-Klage zur OPZELURA-Line-Extension-Klassifizierung (218,5 Mio. USD Rückstellung) sowie der CEO-Wechsel in der Jahresmitte 2025. Mit 3,58 Mrd. USD Liquidität und positivem operativem Cashflow von 1,41 Mrd. USD ist die Bilanz solide, doch die Abhängigkeit von JAKAFI (71% der Produktumsätze) bleibt das zentrale strategische Risiko. Red Flags:
|
||||||
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (30.03.2026)
HOCH Abgang Schlüsselpersonen (26.03.2026)
HOCH Abgang Schlüsselpersonen (30.03.2026)
HOCH Abgang Schlüsselpersonen (26.03.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 30.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 26.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 12.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 03.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 07.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 27.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 10.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 12.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 15.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 04.10.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 21.04.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.01.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 28.09.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 27.05.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 27.05.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.05.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 20.04.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 26.03.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |